Drug Profile
Bevacizumab biosimilar - Celltrion
Alternative Names: Begzelma; CT-16; CT-P16; VegzelmaLatest Information Update: 15 Nov 2023
Price :
$50
*
At a glance
- Originator Celltrion
- Developer Celltrion; Nippon Kayaku
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Breast cancer; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Glioma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma
- Registered Glioblastoma